A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD.
A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD.
复制标题
DOI：
10.1182/bloodadvances.2023010676
复制
发表时间：
2023-10-24
期刊：
影响因子：
7.5
通讯作者：
中科院分区：
文献类型：
--
作者：
成人SCD患者将使用通过mHealth应用程序提供的面向患者的指南。该试验的结果对改善患者教育和减少成人SCD患者的住院治疗具有重要意义。尽管针对镰状细胞病（SCD）的循证指南数量有所增加，但尚未评估以外行语言向患有SCD的个人或家庭传播循证指南的情况。我们进行了一项可行性随机对照试验，以确定具有面向患者的指南的移动的健康（mHealth）应用程序的可接受性，以提高SCD患者对SCD特定知识的了解并减少住院治疗。主要结果指标包括招募率、保留率和依从率。2018年至2022年期间，2家镰状细胞中心招募了SCD成人患者。参与者被随机分配接受mHealth应用程序+面向患者的指南小册子或仅包含指南的小册子。参与者完成了基线调查和最后6个月的访问。74例患者中约有67例（91%）同意参与并接受随机化，67例患者中有50例（75%）完成了所有研究组成部分。在治疗组完成研究的所有参与者都使用了该应用程序。我们的结果表明，在SCD成人中进行的第一项随机试验中，采用面向患者的指南的mHealth应用程序的招募率、保留率和依从率都很高。该临床试验在https://www.clinicaltrials.gov/注册为#NCT03629678。
Adults with SCD will use patient-facing guidelines delivered through an mHealth app. The results of the trial have implications for improving patient education and reducing hospitalizations for adults with SCD. Despite the increased number of evidence-based guidelines for sickle cell disease (SCD), dissemination of evidence-based guidelines in lay language for individuals or families with SCD has not been evaluated. We conducted a feasibility randomized controlled trial to determine the acceptability of a mobile health (mHealth) app with patient-facing guidelines to improve the knowledge of individuals with SCD about SCD-specific knowledge and reduce hospitalizations. Primary outcome measures include recruitment, retention, and adherence rates. Adults with SCD were enrolled at 2 sickle cell centers between 2018 and 2022. Participants were randomized to receive either an mHealth app + booklet with patient-facing guidelines or a booklet with the guidelines alone. Participants completed surveys at baseline and a final 6-month visit. Approximately 67 of 74 (91%) agreed to participate and were randomized, with 50 of 67 (75%) completing all the study components. All participants who completed the study in the treatment arm used the app. Our results demonstrated high recruitment, retention, and adherence rate for the first randomized trial for an mHealth app with patient-facing guidelines in adults with SCD. This clinical trial was registered at https://www.clinicaltrials.gov/ as #NCT03629678.
登录
查看更多内容
影响因子：
13.8
作者：
Reeves, Sarah L.;Peng, Hannah K.;Wing, Jeffrey J.;Cogan, Lindsay W.;Goel, Alka;Anders, David;Green, Nancy S.;Lisabeth, Lynda D.;Dombkowski, Kevin J.
通讯作者：
Dombkowski, Kevin J.
影响因子：
3.2
作者：
Raphael, Jean L.;Shetty, Priya B.;Mueller, Brigitta U.
通讯作者：
Mueller, Brigitta U.
影响因子：
12.8
作者：
Beverung, Lauren M.;Brousseau, David;Panepinto, Julie A.
通讯作者：
Panepinto, Julie A.
影响因子：
3.6
作者：
Jonassaint, Charles R.;Kang, Chaeryon;Sarkar, Urmimala
通讯作者：
Sarkar, Urmimala
影响因子：
4
作者：
Abshire M;Dinglas VD;Cajita MI;Eakin MN;Needham DM;Himmelfarb CD
通讯作者：
Himmelfarb CD